Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasmsBenefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms, Published online: 28 February 2018; doi:10.1038/s41408-018-0048-9Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms

Source: Blood Cancer Journal - February 28, 2018 Category: Hematology Authors: Valerio De Stefano Alessandra Carobbio Vincenzo Di Lazzaro Paola Guglielmelli Alessandra Iurlo Maria Chiara Finazzi Elisa Rumi Francisco Cervantes Elena Maria Elli Maria Luigia Randi Martin Griesshammer Francesca Palandri Massimiliano Bonifacio Juan-Carlo Source Type: research